D C Cumberland
Overview
Explore the profile of D C Cumberland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holt C, Gunn J, Lambert D, Cumberland D, Crossman D
Methods Mol Med
. 2011 Feb;
30:401-15.
PMID: 21341043
Antisense oligonucleotides are short segments of synthetic DNA designed to contain sequences of bases complementary to the DNA or RNA of a particular target gene of interest. By binding to...
2.
Chan K, Armstrong J, Withers S, Malik N, Cumberland D, Gunn J, et al.
Biomaterials
. 2006 Nov;
28(6):1218-24.
PMID: 17126396
c-Myc is involved in the formation of neointimal hyperplasia. We investigated in vitro, ex vivo and in vivo release of antisense c-myc from cationically modified phosphorylcholine-coated stents, as well as...
3.
Bakhai A, Booth J, Delahunty N, Nugara F, Clayton T, McNeill J, et al.
Int J Cardiol
. 2005 Jun;
102(1):95-102.
PMID: 15939104
Objective: To evaluate the use of the phosphorylcholine (PC) coated BiodivYsio small vessel (SV) stent in native coronary vessels of small calibre. Design And Setting: Prospective, multi-centre, multi-national registry with...
4.
Pollard S, Munks K, Wales C, Crossman D, Cumberland D, Oakley G, et al.
Heart
. 2003 Mar;
89(4):447-8.
PMID: 12639880
No abstract available.
5.
Gunn J, Morton A, Wales C, Newman C, Crossman D, Cumberland D
Heart
. 2003 Jan;
89(2):127-31.
PMID: 12527654
A policy of selective implantation of drug eluting stents, in a minority of lesions most likely to benefit, seems to be a rational way to employ this new and currently...
6.
BOLAND J, Corbeij H, van der Giessen W, Seabra-Gomes R, Suryapranata H, Wijns W, et al.
Int J Cardiovasc Intervent
. 2002 Nov;
3(4):215-225.
PMID: 12431346
AIMS: The BiodivYsio trade mark stent (Biocompatibles Ltd, Farnham, UK) is coated with a phosphorylcholine (PC)-containing copolymer to confer biocompatibility. The SOPHOS (Study Of PHosphorylcholine coating On Stents) study was...
7.
Gunn J, Arnold N, Chan K, Shepherd L, Cumberland D, Crossman D
Heart
. 2002 Sep;
88(4):401-5.
PMID: 12231603
Objective: To investigate the relative importance of stent induced arterial stretch and deep injury to the development of in-stent neointima. Setting: Normal porcine coronary arteries Methods: 30 BiodivYsio stents (Biocompatibles)...
8.
Lambert D, Malik N, Shepherd L, Gunn J, Francis S, King A, et al.
Arterioscler Thromb Vasc Biol
. 2001 Nov;
21(11):1727-32.
PMID: 11701457
Previous studies have shown that inhibition of the proto-oncogene c-myb inhibits neointimal formation in various animal models. However, the temporal and spatial expression of c-Myb in the vessel wall after...
9.
Francis S, Camp N, Burton A, Dewberry R, Gunn J, Cumberland D, et al.
Heart
. 2001 Aug;
86(3):336-40.
PMID: 11514491
Background: Percutaneous transluminal coronary angioplasty (PTCA) is limited by the recurrence of luminal stenosis, which occurs in up to 50% of procedures. It has been shown that patient specific factors,...
10.
Newman C, Lawrie A, Brisken A, Cumberland D
Echocardiography
. 2001 Jun;
18(4):339-47.
PMID: 11415507
The promise of gene therapy lies in the potential to ameliorate or cure conditions that are resistant to conventional therapeutic approaches. Progress in vascular and all other fields of gene...